All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F16%3A%230006959" target="_blank" >RIV/00023884:_____/16:#0006959 - isvavai.cz</a>

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation

  • Original language description

    The PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy) trials revealed that in atrial fibrillation (AF) patients suitable for oral anticoagulation (OAC), mechanical left atrial appendage closure (LAAC) with a catheter-delivered heart implant device (Watchman; Boston Scientific, Marlborough, Massachusetts) is effective for stroke prevention 1 and 2. Importantly, these patients received at least 6 weeks of OAC. Although there is no randomized LAAC trial in OAC-contraindicated patients, there is 1 prospective nonrandomized study of Watchman in these patients (n = 150; CHA2DS2-VASc [Congestive heart failure; Hypertension; Age; Diabetes mellitus; prior Stroke, TIA, or thromboembolism; Vascular disease; Age; Sex category {female}] score = 4.4) (3). In this trial, ASAP (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology), the post-implantation annual ischemic stroke rate was 1.7%, representing 77% fewer strokes than expected for this population. Although promising, the mean follow-up in ASAP was only 1.2 years, so there have been few long-term data regarding LAAC in OAC-contraindicated patients. Herein, we report the 5-year follow-up of ASAP.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of the American College of Cardiology

  • ISSN

    0735-1097

  • e-ISSN

  • Volume of the periodical

    67

  • Issue of the periodical within the volume

    18

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    3

  • Pages from-to

    2190-2192

  • UT code for WoS article

    000375406100016

  • EID of the result in the Scopus database

    2-s2.0-84966526573